Management of hepatitis B virus

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 2, 2008, Pages 224-228

  Singh, Nidhi A ^a   Reau, Nancy ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

HBV; Therapy; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CANCER RISK; CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; DNA DETERMINATION; DRUG CHOICE; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG TOLERABILITY; EARLY INTERVENTION; EDITORIAL; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOLOGICAL TOLERANCE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LONG TERM CARE; MEDICAL LITERATURE; MONOTHERAPY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PATIENT MONITORING; PRACTICE GUIDELINE; PROGNOSIS; RECURRENT DISEASE; RELAPSE; RISK ASSESSMENT; RISK REDUCTION; SEROCONVERSION; TREATMENT DURATION; VIREMIA; VIRUS DETECTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

DISEASE MANAGEMENT; HEPATITIS B; HUMANS;

EID: 47249090580     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn188     Document Type: Editorial

References (35)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
2. Lok A, McMahon B. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
3. Alter M. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003; 23: 39-46.
4. Bosch F, Ribes J, Cleries R et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 191-211.
5. Chen C, Yang H, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. J Am Med Assoc 2006; 295: 65-73.
6. Iloege U, Yang H, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
7. Yang H, Lu S, Liaw Y et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-74.
8. Locamini S, Birch C. Antiviral chemotherapy for chronic hepatitis B infection: Lessons learned from treating HIV-infected patients. J Hepatol 1999; 30: 536-50.
9. Liaw Y, Sung J, Chow W et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351 1521-31.
10. Lai C, Dienstag J, Schiff E et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 3: 687-96.
11. Yang H, Qi X, Sabogal A et al. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10: 625-33.
12. Lampertico P, Vigano M, Manenti E et al. Low resistance to adefovir combined with lamivudine: A 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445-51.
13. Colonno R, Rose R, Pokonowski K et al. Four-year assessment of ETV resistance in nucleoside-naïve and lamivudine refractory patients. In: Abstracts of the Forty-second Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain, 2007. Abstract 781.
14. Viola L, Harrison I, Coleman J et al. Natural history of liver disease in chronic hepatitis B surface antigen carriers: Survey of 100 patients from Great Britain. Lancet 1981; ii: 1156-9.
15. Liaw Y, Chu C, Su I et al. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983; 84: 216-9.
16. Fattovich G, Rugge M, Brollo L et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986; 6: 167-72.
17. Yuen M, Yuan H, Wong D et al. Prognostic determinants for chronic hepatitis B in Asians: Therapeutic implications. Gut 2005; 54 1610-4.
18. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-7.
19. Lok A, Lai C, Wu P et al. Spontaneous hepatitis e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92: 1839-43.
20. Hsu Y, Chien R, Yeh C et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522-7.
21. Lim S, Oo A, Wasser S. Treatment-induced HbeAg seroconversion is a poor therapeutic endpoint. Hepatology 2007; 46: A-937.
22. Yuan H, Yuen M, Ka-Ho Wong D et al. The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. J Viral Hepat 2005; 12: 373-9.
23. Okamoto H, Tsuda F, Akahane Y et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994; 68: 8102-10.
24. Chen C, Yang H, Iloeje U et al. Changes in serum HBV DNA level using a trajectory model predict the risk of HCC in chronic hepatitis B patients: The R.E.V.E.A.L.-HBV study. Hepatology 2007; 46: 639A [Abstract 906].
25. Wong D, Lai C, Fung J et al. Large scale longitudinal study of chronic hepatitis B patients with hepatitis B surface antigen seroclearance. Hepatology 2007; 46: 637A [Abstract 900].
26. Kim H, Nam C, Jee S et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: Prospective cohort study. Br Med J 2004; 328: 983.
27. Prati D, Taioli E, Zanella A et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
28. Lai M, Hyatt B, Nasser I et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007; 47: 760-7.
29. Park J, Park Y, Kim D et al. A high prevalence of significant liver disease in asymptomatic hepatitis B patients with high viral load: candidates for antiviral therapy. Hepatology 2007; 46: 656A [Abstract 942].
30. Keefe E, Dieterich D, Han S et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936-62.
31. Lok A. Navigating the maze of hepatitis B treatments. Gastroenterology 2007; 132: 1586-94.
32. Kim J, Joo M, Lee S et al. Durability of antiviral response in lamivudine treated HbeAg positive chronic hepatitis B patients who did not relapse within a year of post treatment. Hepatology 2007; 46: A-947.
33. Hadziyannis S, Sevastianos V, Rapti I et al. Sustained biochemical and virologic remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg-negative chronic hepatitis B. Hepatology 2006; 44: 231A-232A [Abstract 114].
34. Marcellin P, Bonino F, Lau GK et al. Suppression of HBV DNA in patients with HBeAg-negative CHB treated with peginterferon alfa-2a (40 kd) ± lamivudine: 2 year follow-up results. Hepatology 2006; 44: 550A [Abstract 972].
35. Yim HJ, Hussain M, Liu Y et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44: 703-12.